Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Atripla

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products

Merck has suggested Delstrigo is slightly more effective than Gilead’s widely-prescribed Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), which made $1.3bn in sales last year.

Gilead gets EU nod for TAF-based triple therapy for HIV

Gilead gets EU nod for TAF-based triple therapy for HIV Atripla in 20016. ... Since then, Atripla has grown into a $3bn-plus product. "People living with HIV today are increasingly likely to be receiving treatment for other conditions - such as heart and liver disease -

ViiV and Janssen take long-acting HIV regimen into phase III

ViiV and Janssen take long-acting HIV regimen into phase III Gilead currently dominates the HIV treatment sector thanks to drugs like Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (favirenz/emtricitabine/tenofovir disoproxil fumarate), but ViiV is fighting back.

ViiV agrees $1.5bn deal to acquire BMS' HIV assets

ViiV agrees $1.5bn deal to acquire BMS' HIV assets cobicistat), Sustiva (efavirenz) and big-selling Atripla (efavirenz, emtricitabine, and tenofovir).

ViiV boosted by positive phase III results for HIV drug Triumeq

ViiV boosted by positive phase III results for HIV drug Triumeq The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.

1 2 3 4 5 6 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics